$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000145368724000036 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$5.840M	$8.266M	$26.00M
YoY Change	-1.65%	-50.78%	-76.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.450M	$22.07M	$40.48M
YoY Change	65.94%	248.94%	69.65%
% of Gross Profit
Research & Development	$9.738M	$21.83M	$71.84M
YoY Change	-47.71%	15.1%	-0.74%
% of Gross Profit
Depreciation & Amortization	$200.0K	$272.0K	$700.0K
YoY Change	0.0%	12.86%	0.0%
% of Gross Profit
Operating Expenses	$19.19M	$43.90M	$112.4M
YoY Change	-21.1%	73.57%	16.81%
Operating Profit	-$13.35M		-$86.42M
YoY Change	-27.38%		-694.41%
Interest Expense	$0.00	-$148.7M	$2.833M
YoY Change	-100.0%	-39955.5%	-6.53%
% of Operating Profit
Other Income/Expense, Net	$508.0K	-$11.67M	$691.0K
YoY Change	99.22%	-184.97%	109.39%
Pretax Income	-$56.82M	-$196.7M	-$238.7M
YoY Change	162.31%	-3608.62%	-786.54%
Income Tax		-$19.00M	-$19.00M
% Of Pretax Income
Net Earnings	-$56.82M	-$177.7M	-$219.7M
YoY Change	162.31%	-3114.73%	-721.02%
Net Earnings / Revenue	-973.01%	-2149.26%	-844.91%
Basic Earnings Per Share	-$10.50		-$1.66
Diluted Earnings Per Share	-$10.50	-$1.12	-$1.66
COMMON SHARES
Basic Shares Outstanding	161.9M shares	155.2M	155.1M shares
Diluted Shares Outstanding	5.414M shares		155.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.4M	$76.91M	$76.91M
YoY Change	-17.87%	-42.86%	-42.86%
Cash & Equivalents	$103.4M	$76.91M	$76.91M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$3.315M	$4.967M	$4.967M
YoY Change	-12.42%	31.47%	31.47%
Inventory
Prepaid Expenses
Receivables	$2.006M	$5.870M	$5.870M
Other Receivables	$2.370M	$2.981M	$2.981M
Total Short-Term Assets	$111.1M	$90.73M	$90.73M
YoY Change	-19.71%	-38.75%	-38.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.402M	$2.113M	$12.18M
YoY Change	-13.13%	-24.37%	-15.47%
Goodwill	$48.16M	$48.16M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$2.000M	$2.000M
YoY Change	0.0%	0.0%	0.0%
Other Assets	$1.377M	$1.377M	$1.377M
YoY Change	3.15%	2.99%	2.99%
Total Long-Term Assets	$214.1M	$214.3M	$214.3M
YoY Change	1137.49%	1107.58%	1107.58%
TOTAL ASSETS
Total Short-Term Assets	$111.1M	$90.73M	$90.73M
Total Long-Term Assets	$214.1M	$214.3M	$214.3M
Total Assets	$325.2M	$305.1M	$305.1M
YoY Change	108.88%	83.89%	83.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.517M	$3.150M	$3.150M
YoY Change	136.78%	896.84%	896.84%
Accrued Expenses	$8.927M	$14.73M	$17.74M
YoY Change	-4.49%	4.61%	13.04%
Deferred Revenue	$412.0K	$2.311M
YoY Change	-90.26%	289.71%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$36.65M	$68.21M	$68.21M
YoY Change	38.16%	172.0%	172.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$389.5M	$360.6M	$360.6M
YoY Change	915.51%	1135.2%	1135.2%
Total Long-Term Liabilities	$389.5M	$360.6M	$360.6M
YoY Change	613.59%	667.58%	667.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.65M	$68.21M	$68.21M
Total Long-Term Liabilities	$389.5M	$360.6M	$360.6M
Total Liabilities	$442.0M	$444.7M	$444.7M
YoY Change	444.92%	517.11%	517.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$671.5M	-$614.6M
YoY Change	61.19%	55.63%
Common Stock	$1.000K	$16.00K
YoY Change	-93.33%	6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$116.8M	-$440.2M	-$139.6M
YoY Change
Total Liabilities & Shareholders Equity	$325.2M	$305.1M	$305.1M
YoY Change	108.88%	83.89%	83.89%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$56.82M	-$177.7M	-$219.7M
YoY Change	162.31%	-3114.73%	-721.02%
Depreciation, Depletion And Amortization	$200.0K	$272.0K	$700.0K
YoY Change	0.0%	12.86%	0.0%
Cash From Operating Activities	-$15.92M	-$23.29M	-$51.16M
YoY Change	81.6%	96.52%	61.74%
INVESTING ACTIVITIES
Capital Expenditures	$602.0K	$64.00K	$206.0K
YoY Change	363.08%	-69.67%	-82.85%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$6.561M	$34.82M
YoY Change	-100.0%	15.11%	-352.26%
Cash From Investing Activities	-$602.0K	$6.497M	$34.61M
YoY Change	-102.14%	18.36%	-330.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$27.46M
YoY Change
Cash From Financing Activities	$43.03M	14.08M	-$13.15M
YoY Change	28779.87%		-133.52%
NET CHANGE
Cash From Operating Activities	-$15.92M	-23.29M	-$51.16M
Cash From Investing Activities	-$602.0K	6.497M	$34.61M
Cash From Financing Activities	$43.03M	14.08M	-$13.15M
Net Change In Cash	$26.51M	-2.708M	-$29.75M
YoY Change	36.02%	-57.42%	302.14%
FREE CASH FLOW
Cash From Operating Activities	-$15.92M	-$23.29M	-$51.16M
Capital Expenditures	$602.0K	$64.00K	$206.0K
Free Cash Flow	-$16.52M	-$23.35M	-$51.37M
YoY Change	85.71%	93.62%	56.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Net Derivative Asset Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#GainLossOnDerivativeInstrumentsNetPretax
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37798
CY2023	dei	Entity Registrant Name EntityRegistrantName	Cartesian Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1622110
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	704 Quince Orchard Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	923-1400
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	RNAC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	128805952	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161948618	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76911000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106438000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28164000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5870000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6596000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2981000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	3162000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4967000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3778000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	90729000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	148138000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2113000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2794000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10068000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11617000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	150600000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	48163000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1377000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	2000000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	0	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	26000	usd
CY2023Q4	us-gaap	Assets Assets	305050000	usd
CY2022Q4	us-gaap	Assets Assets	165886000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3150000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	316000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15572000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14084000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	8476000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2166000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1608000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2311000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	593000	usd
CY2023Q4	rnac	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	720000	usd
CY2022Q4	rnac	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	0	usd
CY2023Q4	rnac	Contingent Value Right Liability Current ContingentValueRightLiabilityCurrent	15983000	usd
CY2022Q4	rnac	Contingent Value Right Liability Current ContingentValueRightLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	28307000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68209000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25077000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	17786000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8789000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10055000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3538000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2023Q4	rnac	Warrants And Rights Outstanding Noncurrent WarrantsAndRightsOutstandingNoncurrent	5674000	usd
CY2022Q4	rnac	Warrants And Rights Outstanding Noncurrent WarrantsAndRightsOutstandingNoncurrent	19140000	usd
CY2023Q4	rnac	Contingent Value Right Liability Noncurrent ContingentValueRightLiabilityNoncurrent	342617000	usd
CY2022Q4	rnac	Contingent Value Right Liability Noncurrent ContingentValueRightLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15853000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	444680000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	72058000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	548375	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	435120.513	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	435120.513	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	296851000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	3703000	usd
CY2022Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161927821	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153042435	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	493308000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394937000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4558000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	93828000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165886000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68736000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-86416000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	4964000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	2073000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	38000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	2833000	usd
CY2022	us-gaap	Interest Expense InterestExpense	3031000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2844000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12746000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20882000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2339000	usd
CY2023	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	18300000	usd
CY2022	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2021	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-149600000	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	691000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	330000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-238710000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34770000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9721000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-609000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15966000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-219710000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35379000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-25687000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	18000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-219752000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	35387000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25690000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155109561	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144758555	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114328798	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155109561	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145874889	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114328798	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2020Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	0	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-18006000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	161000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	778000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	51934000	usd
CY2021	rnac	Stock Issued During Period Value Common Warrants Exercised StockIssuedDuringPeriodValueCommonWarrantsExercised	5624000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7720000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22521000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	189000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	156000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2121000	usd
CY2022	rnac	Stock Issued During The Period Values Common Stock And Warrants StockIssuedDuringThePeriodValuesCommonStockAndWarrants	21480000	usd
CY2022	rnac	Stock Issued During The Period Values Common Stock License Agreement StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement	1000000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	780000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10194000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	18000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35379000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	93828000	usd
CY2023	rnac	Temporary Equity Stock Issued During Period Acquisitions Shares TemporaryEquityStockIssuedDuringPeriodAcquisitionsShares	384930.724	shares
CY2023	rnac	Temporary Equity Stock Issued During Period Acquisitions Value TemporaryEquityStockIssuedDuringPeriodAcquisitionsValue	261753000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	231000	usd
CY2023	rnac	Adjustments To Additional Paid In Capital Issuance Of Common Stock Forward In Connection With The Merger AdjustmentsToAdditionalPaidInCapitalIssuanceOfCommonStockForwardInConnectionWithTheMerger	2713000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	usd
CY2023	rnac	Temporary Equity Options Issuance Of Replacement Options In Merger TemporaryEquityOptionsIssuanceOfReplacementOptionsInMerger	3643000	usd
CY2023	rnac	Adjustments To Additional Paid In Capital Issuance Of Replacement Options In Merger AdjustmentsToAdditionalPaidInCapitalIssuanceOfReplacementOptionsInMerger	6801000	usd
CY2023	rnac	Stock Issued During The Period Values Common Stock License Agreement StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement	1500000	usd
CY2023	rnac	Adjustments To Additional Paid In Capital Settlement Of Outstanding Equity Awards AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards	6169000	usd
CY2023	rnac	Adjustments To Additional Paid In Capital Distribution Of Contingent Value Rights AdjustmentsToAdditionalPaidInCapitalDistributionOfContingentValueRights	340300000	usd
CY2023	rnac	Temporary Equity Options Share Based Payment Arrangement Increase For Cost Recognition TemporaryEquityOptionsShareBasedPaymentArrangementIncreaseForCostRecognition	60000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20964000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-219710000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	435120.513	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	296851000	usd
CY2023Q4	rnac	Temporary Equity Options Carrying Amount Attributable To Parent TemporaryEquityOptionsCarryingAmountAttributableToParent	3703000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-440184000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-219710000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35379000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-25687000	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	843000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1287000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1252000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	79000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	375000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-57000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1754000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1337000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1119000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	710000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-477000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	147000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	22524000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11194000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7720000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	455000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	953000	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	1012000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12746000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20882000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2339000	usd
CY2023	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	18300000	usd
CY2022	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2021	rnac	Fair Value Adjustment Of Contingent Value Right Liability FairValueAdjustmentOfContingentValueRightLiability	0	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-149600000	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-740000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-19000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-726000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3318000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2690000	usd
CY2023	rnac	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	-181000	usd
CY2022	rnac	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	3162000	usd
CY2021	rnac	Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1265000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2471000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1451000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2834000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	92000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-219000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-601000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	601000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5256000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-64707000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-45496000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2761000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2212000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1061000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51161000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31631000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60382000	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	6561000	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	28254000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	19700000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	16400000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	2000000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	33501000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	30455000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	206000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1201000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1085000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34609000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15002000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17140000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	20250000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	27457000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	110000	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	rnac	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2022	rnac	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	36859000	usd
CY2021	rnac	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2023	rnac	Payment For Settlement Of Equity Awards In Business Combination PaymentForSettlementOfEquityAwardsInBusinessCombination	6169000	usd
CY2022	rnac	Payment For Settlement Of Equity Awards In Business Combination PaymentForSettlementOfEquityAwardsInBusinessCombination	0	usd
CY2021	rnac	Payment For Settlement Of Equity Awards In Business Combination PaymentForSettlementOfEquityAwardsInBusinessCombination	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	156000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	778000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	231000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	189000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	161000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13145000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39215000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52897000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29750000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7398000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24628000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108038000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115436000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140064000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78288000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108038000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115436000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1853000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2248000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2002000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1500000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1000000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023	rnac	Noncash Or Part Noncash Warrant Exercises NoncashOrPartNoncashWarrantExercises	0	usd
CY2022	rnac	Noncash Or Part Noncash Warrant Exercises NoncashOrPartNoncashWarrantExercises	0	usd
CY2021	rnac	Noncash Or Part Noncash Warrant Exercises NoncashOrPartNoncashWarrantExercises	5624000	usd
CY2023	rnac	Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity NoncashOrPartNoncashReclassificationOfWarrantLiabilityToEquity	0	usd
CY2022	rnac	Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity NoncashOrPartNoncashReclassificationOfWarrantLiabilityToEquity	780000	usd
CY2021	rnac	Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity NoncashOrPartNoncashReclassificationOfWarrantLiabilityToEquity	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	224000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	rnac	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	78300000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1400000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-614600000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: estimated fair value of the intangible assets acquired in connection with the Merger, estimated fair value of the CVRs, deferred income taxes, revenue recognition and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.66
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term deposits and marketable securities, investments, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially creditworthy and, accordingly, minimal risk exists with respect to those balances. The Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars.
CY2023	rnac	Adjustments To Additional Paid In Capital Settlement Of Outstanding Equity Awards AdjustmentsToAdditionalPaidInCapitalSettlementOfOutstandingEquityAwards	6200000	usd
CY2023Q4	rnac	Share Based Compensation Arrangement By Share Based Payment Award Settlement Of Awards Stock Based Compensation Expense Recognized On Settlement ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsStockBasedCompensationExpenseRecognizedOnSettlement	3200000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3255000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-19000000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-600000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000000	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	1300000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2806000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5892000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	705000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1697000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	84626000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	26004000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	112226000	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-232259000	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	29607000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	83417000	usd
CY2023Q4	rnac	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2718000	usd
CY2022Q4	rnac	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	3186000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	19778000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9588000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28175000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28164000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-219710000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35379000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-25687000	usd
CY2023	us-gaap	Distributed Earnings DistributedEarnings	37550000	usd
CY2022	us-gaap	Distributed Earnings DistributedEarnings	0	usd
CY2021	us-gaap	Distributed Earnings DistributedEarnings	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-257260000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	35379000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25687000	usd
CY2023	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2022	us-gaap	Dilutive Securities DilutiveSecurities	-20882000	usd
CY2021	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-257260000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14497000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25687000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155109561	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144758555	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114328798	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1116334	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155109561	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145874889	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114328798	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.66
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	602904502	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18013373	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22227982	shares
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76911000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106438000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114057000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	289000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1377000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1311000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78288000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108038000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115436000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	9140000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7472000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	152465000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	131073000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	41144000	usd
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	148710.488	shares
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	0	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	155308000	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	276601000	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings	-149600000	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	28307000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7841000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7999000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5728000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5205000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2113000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2794000	usd
CY2023	us-gaap	Depreciation Depreciation	700000	usd
CY2022	us-gaap	Depreciation Depreciation	700000	usd
CY2021	us-gaap	Depreciation Depreciation	600000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4390000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4242000	usd
CY2023Q4	rnac	Accrued Patent Fees Current AccruedPatentFeesCurrent	472000	usd
CY2022Q4	rnac	Accrued Patent Fees Current AccruedPatentFeesCurrent	696000	usd
CY2023Q4	rnac	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4896000	usd
CY2022Q4	rnac	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	7274000	usd
CY2023Q4	rnac	Accrued Audit Fees Current AccruedAuditFeesCurrent	4331000	usd
CY2022Q4	rnac	Accrued Audit Fees Current AccruedAuditFeesCurrent	985000	usd
CY2023Q4	rnac	Accrued Interest Current AccruedInterestCurrent	0	usd
CY2022Q4	rnac	Accrued Interest Current AccruedInterestCurrent	222000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	644000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	665000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14733000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14084000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2828000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2276000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2023000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	965000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	910000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	834000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	1172000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	176000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	2629000	usd
CY2022	us-gaap	Lease Cost LeaseCost	3021000	usd
CY2021	us-gaap	Lease Cost LeaseCost	2867000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	128000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	81000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2751000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3174000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3077000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3164000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3248000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3017000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	946000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13452000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2497000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10955000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2696000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2048000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.099
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	2100000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	3000000.0	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2800000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	548375	shares
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	148710.488	shares
CY2023Q4	rnac	Settlement Of Derivative Liability Shares SettlementOfDerivativeLiabilityShares	49570.162	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	435120.513	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	435120.513	shares
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1000
CY2023	rnac	Preferred Stock Redemption Term PreferredStockRedemptionTerm	P18M
CY2023	rnac	Preferred Stock Convertible Threshold Consecutive Trading Days PreferredStockConvertibleThresholdConsecutiveTradingDays	10	day
CY2023Q4	rnac	Preferred Stock Convertible Transaction Restrictions Percentage Of Originally Issued Stock Issued And Outstanding PreferredStockConvertibleTransactionRestrictionsPercentageOfOriginallyIssuedStockIssuedAndOutstanding	0.30
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	44023000	usd
CY2023Q4	rnac	Temporary Equity Shares Reserved For Future Issuance TemporaryEquitySharesReservedForFutureIssuance	113252.625	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10735980	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.62
CY2022	rnac	Stock Issued During Period Shares Warranted Issued StockIssuedDuringPeriodSharesWarrantedIssued	20571429	shares
CY2022	rnac	Stock Issued During Warranted Issued Price Per Share StockIssuedDuringWarrantedIssuedPricePerShare	1.55
CY2022	rnac	Stock Issued During Period Shares Warrants Canceled StockIssuedDuringPeriodSharesWarrantsCanceled	79130	shares
CY2022	rnac	Stock Issued During Warranted Canceled Price Per Share StockIssuedDuringWarrantedCanceledPricePerShare	17.71
CY2022	rnac	Stock Issued During Period Shares Warrant Reclassification To Equity StockIssuedDuringPeriodSharesWarrantReclassificationToEquity	0	shares
CY2022	rnac	Stock Issued During Warrant Reclassification To Equity Price Per Share StockIssuedDuringWarrantReclassificationToEquityPricePerShare	1.46
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31228279	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.53
CY2023	rnac	Stock Issued During Period Shares Warrants Canceled StockIssuedDuringPeriodSharesWarrantsCanceled	3576	shares
CY2023	rnac	Stock Issued During Warranted Canceled Price Per Share StockIssuedDuringWarrantedCanceledPricePerShare	16.77
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31224703	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.53
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161927821	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161927821	shares
CY2023Q4	rnac	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1	vote
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	90367632	shares
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1000
CY2023Q4	rnac	Share Based Compensation Arrangement By Share Based Payment Award Settlement Of Awards Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount	2.06
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	13100000	usd
CY2023Q4	rnac	Share Based Compensation Arrangement By Share Based Payment Award Settlement Of Awards Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount	2.06
CY2023Q4	rnac	Share Based Compensation Arrangement By Share Based Payment Award Settlement Of Awards Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwardsAmount	2.06
CY2023Q4	rnac	Share Based Compensation Arrangement By Share Based Payment Award Settlement Of Awards ShareBasedCompensationArrangementByShareBasedPaymentAwardSettlementOfAwards	9400000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25778000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11194000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7720000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5800000	usd
CY2022Q4	rnac	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	593000	usd
CY2023	rnac	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	10500000	usd
CY2023	rnac	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	5244000	usd
CY2023Q4	rnac	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	5849000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	593000	usd
CY2023	rnac	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	10500000	usd
CY2023	rnac	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	5244000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5849000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-1.660
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.016
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.186
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.083
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.550
CY2023	rnac	Effective Income Tax Rate Reconciliation Deferred Revenue Percent EffectiveIncomeTaxRateReconciliationDeferredRevenuePercent	0
CY2022	rnac	Effective Income Tax Rate Reconciliation Deferred Revenue Percent EffectiveIncomeTaxRateReconciliationDeferredRevenuePercent	0
CY2021	rnac	Effective Income Tax Rate Reconciliation Deferred Revenue Percent EffectiveIncomeTaxRateReconciliationDeferredRevenuePercent	1.565
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.037
CY2023	rnac	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contract Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent	-0.132
CY2022	rnac	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contract Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent	0
CY2021	rnac	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contract Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContractLiabilitiesPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.044
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2.301
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.052
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.080
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.642
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29841000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17015000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5649000	usd
CY2023Q4	rnac	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	108442000	usd
CY2022Q4	rnac	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	127818000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	124295000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	127818000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15853000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3500000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1500000	usd
CY2023	rnac	Capitalized Research And Experimental Costs Tax Purposes CapitalizedResearchAndExperimentalCostsTaxPurposes	44700000	usd
CY2022	rnac	Capitalized Research And Experimental Costs Tax Purposes CapitalizedResearchAndExperimentalCostsTaxPurposes	29300000	usd
CY2023	rnac	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P2Y
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2023	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.79
CY2023	us-gaap	Restructuring Charges RestructuringCharges	6400000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2500000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	6431000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2535000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	3896000	usd

Files In Submission

Name	View Source	Status
0001453687-24-000036-index-headers.html	Edgar Link	pending
0001453687-24-000036-index.html	Edgar Link	pending
0001453687-24-000036.txt	Edgar Link	pending
0001453687-24-000036-xbrl.zip	Edgar Link	pending
exhibit1011aleaseagreement.htm	Edgar Link	pending
exhibit1011bfirstamendment.htm	Edgar Link	pending
exhibit1011csecondamendmen.htm	Edgar Link	pending
exhibit1012leasebetween749.htm	Edgar Link	pending
exhibit1015bamendmentno1to.htm	Edgar Link	pending
exhibit1016patentlicenseno.htm	Edgar Link	pending
exhibit1017patentlicenseag.htm	Edgar Link	pending
exhibit1021astellaslicense.htm	Edgar Link	pending
exhibit106non-employeedire.htm	Edgar Link	pending
exhibit211subsidiariesofca.htm	Edgar Link	pending
exhibit231_12312023.htm	Edgar Link	pending
exhibit311_12312023.htm	Edgar Link	pending
exhibit312_12312023.htm	Edgar Link	pending
exhibit321_12312023.htm	Edgar Link	pending
exhibit414descriptionofsec.htm	Edgar Link	pending
exhibit97compensationclawb.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnac-20231231.htm	Edgar Link	pending
rnac-20231231.xsd	Edgar Link	pending
rnac-20231231_g1.jpg	Edgar Link	pending
rnac-20231231_cal.xml	Edgar Link	unprocessable
rnac-20231231_def.xml	Edgar Link	unprocessable
rnac-20231231_g2.jpg	Edgar Link	pending
rnac-20231231_g3.jpg	Edgar Link	pending
rnac-20231231_g4.jpg	Edgar Link	pending
rnac-20231231_g5.jpg	Edgar Link	pending
rnac-20231231_g6.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
rnac-20231231_pre.xml	Edgar Link	unprocessable
rnac-20231231_htm.xml	Edgar Link	completed
rnac-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2024 Q1 Form 10-K Financial Statement

#000145368724000036 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2024 Q1 Form 10-K Financial Statement

#000145368724000036 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac